ObsEva SA (OBSV) Social Stream

ObsEva SA (OBSV): $2.48

-0.05 (-1.98%)

POWR Rating

Component Grades













Add OBSV to Watchlist
Sign Up

Industry: Biotech


of 499

in industry

Featured Post From StockTwits About OBSV

$OBSV key things to keep in mind:

FDA approval-Q1-Q2 2022
$25M upfront payment is our typical 🔥 rate per quarter
$25M upfront payment is nothing and up to $500M in sales performance this usually takes 3-4 yrs to materialize base on historical deals from big pharma like Pfizer. So technically speaking this is what we call a non traditional partnership deal.

I honestly don’t see any major catalyst to drive the stock price up until 2022 from there o hope they sell this company as they do not have a growth strategy in place. I just hope they find a strong partnership for Linza
techcrunch, published July 27, 2021

Other Notable StockTweets About OBSV

$OBSV There is value in their pipeline. The data is out. And the drugs that are not as developed, the data is positive. Wall Street doesn’t always catch on immediately. Take the chance to buy more shares. Unless you know of another stock that could 5X to 8X in the next year, based on market cap. If you do, please let me know. I’ll buy a crap ton of it too, as I’ve done with Obsv

Robr823, published July 17, 2021

$OBSV [Still True] I began adding (dollar cost averaging) to my position here on the pull-back under $3.00. Anywhere $2.72-2.99 is a good place for me to add, IMO. If the stock should fall between $2.50-2.72 I will add more aggressively. Again-I am adding/increasing my position here slowly in 2H ahead of Phs-III (Yselty) completion and hopefully FDA approval. The Average analyst PT that I have seen for $OBSV, reiterated over the last 30days is $20.50, ranging from $17-24. That is a 6-8X from where we are today, and I believe that is not unreasonable if/when Yselty gains FDA approval in the next 6-9mos.

BinaryLogic, published July 13, 2021

$OBSV what people don’t realize is the Q3 for management means last day of Q3 and it also means zero trust as I wouldn’t be surprised if. They changed they’re pipeline and timelines

techcrunch, published July 9, 2021

Monthly update for June 2/6
$MLSS: 2.10 to 2.25 (Stopped on rest at buy price but went to 2.60+ recently (T3 without stopping out)
$GRAY: 4.38 to 8.52
$IMTE: (Watchlist alert) Went from 4.11 to 5.75
$CLSN: 1.25 to 1.56
$OBSV: 3.03 to 3.33
All alerts were added on ST before the move. I give break out or pullback entry or Accumulation alerts with various targets.
There were some losses too this month but mostly 6-8% but winners were huge. If you trace back my timeline you will see all alerts.
Hope some of you banked huge on some of these.

VIPTrades009, published July 1, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5137 seconds.